Cone Rod Dystrophy Clinical Trials Market Research Report– By Diagnosis (ERG, Clinical History, Fundus Examination, Molecular Diagnosis), By Treatment (Tinted Lenses, Medication, Magnifying Devices), By End User (Hospitals, Ophthalmic Centers) – Global Forecast Till 2023
The Global Cone-Rod Dystrophy Clinical Trials Market Size is expected to grow at a CAGR of approximately 5.3% during the forecast period 2017-2023.
The cone rod dystrophy, also known as cone-rod degeneration, progressive cone-rod dystrophy, and retinal cone dystrophy, is an inherited disease that causes an overtime deterioration of the retina. People with cone-rod dystrophy typically experience decreased clarity of vision followed by a loss of peripheral vision and color blindness. The most common form of cone-rod dystrophy is retinitis pigmentosa.
Increasing age is also one of the major factors for causing ophthalmic complications. A number of changes in the eye muscles and nerves occur as the age increase. According to WHO, 82% of people living with blindness are aged 50 and above. Some ophthalmologists believe that treatment with high doses of Vitamin A can slow the progression. Increased risk of genetic inheritance and increasing geriatric population are the key factors driving the growth of the global cone rod dystrophy market during the forecast period.
This disorder can be curbed to a great extent by proper use of vitamin supplements therefore the cone rod dystrophy market is majorly effected by the Thiamine supplements. The growth of the vitamin industry is due to the increased per-capita income and increased health awareness among people. As the people are getting more aware about taking care of their health, they are giving more importance to these supplements to prevent various deficiencies. Online retailing of these supplements has further increased accessibility and has increased the customer base and it has also increased the convenience of buying which will indirectly effect the Cone Rod Dystrophy market.
Currently, there is no treatment to stop a person with Cone Rod Dystrophy (CRD) from losing their vision. Possible future treatments for CRD may include gene therapy, stem cell therapy, and retinal implants. The beta-carotenoids, lutein and zeaxanthin, have been evidenced to reduce the risk of developing to Cone dystrophy sufferers.
Some of key the players in the global cone rod dystrophy market are GlaxoSmithKline Plc (U.S.), Johnson & Johnson (U.S.), Sanofi (Switzerland), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Abbott Laboratories (U.S.), Sunovion Pharmaceuticals (U.S.), Cephalon (U.S.), DSM (India), Amway (U.S.), Vitamin Shoppe (U.S.), Intas Pharmaceutials Limited (India), Sun Pharmaceuticals Ltd. (India) Emcure Pharmaceuticals Limited (India), Nutrilite (U.S.), NutraScience Labs (U.S.), and others.
Global cone rod dystrophy consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East.
The Americas hold the second largest share of the global cone rod dystrophy market owing to the growing incidence of eye disorders. According to National Eye Institute (NEI), blindness or low vision will affect more than 5.5 million Americans age 40 and over by 2020.
The European market dominated the global cone rod dystrophy market owing to the high prevalence rate of this disease in the Germany and Italy and other Western European countries. The European market is anticipated to compete with the American market during the forecasted period 2017-2023. Target 5000 is a Fighting Blindness research project which aims to provide genetic testing for an estimated 5,000 people in Ireland who are diagnosed with any inherited retinal condition. The purpose of this project is to provide a precise diagnosis and more detailed information about the nature and inheritance pattern of the condition.
The Asia Pacific is expected to be the fastest growing region in the global cone rod dystrophy market.
The cone rod dystrophy is segmented on the basis of diagnosis, treatment, and end-users.
On the basis of the diagnosis, the market is segmented into Electroretinogram (ERG), clinical history, fundus examination, molecular diagnosis, and others.
On the basis of the treatment, the market is segmented into tinted lenses/ dark sunglass, medications, magnifying devices, and surgery. The medication is classified into vitamin A supplement and anticonvulsant.
On the basis of the end-user, the market is segmented into hospitals, ophthalmic centers, research organizations, and academic institutes.